Vitamin D and Glucocorticoid Sensitivity in Obesity-Associated Asthma: A Narrative Review
Keywords:
asthma, obesity, vitamin D, corticosteroid insensitivity, inhaled corticosteroids, IL-10, MKP-1.Abstract
Vitamin D restores glucocorticoid sensitivity in vitro, but this effect has not been demonstrated clinically in obese patients with asthma. This narrative review analyses experimental and clinical data from 2006–2026 on the links between obesity, vitamin D deficiency and corticosteroid insensitivity. Obese asthma patients show reduced corticosteroid efficacy and lower vitamin D levels. In vitro, vitamin D restored dexamethasone-induced IL-10 secretion and MKP-1 expression; observationally, higher vitamin D levels were associated with better lung function and steroid response. However, high-dose vitamin D3 did not reduce treatment failure in the VIDA trial. An individual participant data meta-analysis showed fewer exacerbations requiring systemic corticosteroids, particularly with severe deficiency, whereas a 2023 Cochrane update did not confirm an overall benefit. A blunted response to supplementation in obesity may partly explain these discrepancies. Trials in obese asthma with weight-adjusted dosing, monitoring of serum levels and corticosteroid response as the primary outcome are needed.
References
1.Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175(7):661–666. doi:10.1164/rccm.200611-1717OC
2.Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141(4):1169–1179.
3.Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101(11):2240–2247.
4.Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503.
5.Telenga ED, Tideman SW, Kerstjens HA, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012;67(8):1060–1068.
6.Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178(7):682–687.
7.Tobias DK, Luttmann-Gibson H, Mora S, et al. Association of body weight with response to vitamin D supplementation and metabolism. JAMA Netw Open. 2023;6(1):e2250681.
8.Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006;116(1):146–155. doi:10.1172/JCI21759
9.Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DYM. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med. 2010;181(7):699–704. doi:10.1164/rccm.200911-1710OC
10.Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA. 2014;311(20):2083–2091. doi:10.1001/jama.2014.5052
11.Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017;5(11):881–890. doi:10.1016/S2213-2600(17)30306-5
12.Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database Syst Rev. 2023;2(2):CD011511. doi:10.1002/14651858.CD011511.pub3




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal